An interventional study of Endovascular embolization in Meningioma, sponsored by St. Olavs Hospital. Recruiting at 1 site in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by St. Olavs Hospital · Not applicable, Interventional, and Treatment
The natural course for meningioma suggests that a majority will grow over time. Treatment is usually indicated in growing or symptomatic meningiomas. Surgery is usually primary treatment, but there is a significant risk of adverse effects. Stereotactic radiotherapy is most often reserved to treat relapses after surgery, and except for surgery and radiotherapy there are no other established treatment methods. Endovascular embolization may be used in selected cases as a preoperative adjunct to reduce intraoperative bleeding. There is a need for more treatment options in patients with meningioma, both in uncomplicated, asymptomatic cases and in more complex cases. The aim of this study is to assess radiological and clinical results of therapeutic endovascular embolization for meningioma
Exclusion Criteria:
Procedure: Endovascular embolization
Therapeutic endovascular embolization in general anesthesia
Change in radiological tumor volume from baseline
Volumetric segmentation of tumor volume
Time frame: At 1 year, 3 year and 5 year
Number of participants undergoing re-intervention for meningioma or treatment complications
Surgery or radiotherapy
Time frame: 10 years
Number of participants with epileptic seizures
Time frame: 10 years
Number of participants with moderate or severe procedure related complications within 30 days
Landriel Ibanez classification (grade 3 or 4 complications)
Time frame: 30 days
Change in generic health-related quality of life from baseline
EuroQol-5D 3L (EQ-5D 3L)
Time frame: At 1 months and 6 months
Change in disease-specific quality of life from baseline
The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 questionnaire
Time frame: At 1 months and 6 months
Change in domain-specific quality of life from baseline
The European Organisation for Research and Treatment of Cancer (EORTC) QLQ-BN20 questionnaire
Time frame: At 1 months and 6 months
Change in neurological function
National Institutes of Health Stroke Scale (NIHSS)
Time frame: At 1 month
Number of participants with adverse events
Landriel Ibanez classification
Time frame: 30 days
Number of participants returning to work
Time frame: At 1 months and 6 months
Loss of functional level from baseline
\>10 points in Karnofsky performance status
Time frame: At 1 month and 6 months
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
St. Olavs Hospital